Redefining drug development: Analytics driving quality and compliance

Reddy, M Manivardhan and Ramadevi, K (2025) Redefining drug development: Analytics driving quality and compliance. World Journal of Advanced Research and Reviews, 25 (2). pp. 1650-1663. ISSN 2581-9615

Drug substance development is a cornerstone of pharmaceutical manufacturing, serving as the basis for producing safe, effective, and compliant drug products. Central to this process is the integration of analytical support, which ensures adherence to stringent quality and regulatory standards. Analytical techniques, such as chromatography, spectroscopy, and dissolution testing, are pivotal in assessing the purity, potency, and stability of drug substances, enabling the establishment and maintenance of predefined test parameters and specifications throughout the product lifecycle. Key to this process is the identification and control of critical quality attributes (CQAs), including impurity profiles, particle size, and dissolution rates, to ensure batch-to-batch consistency. Regulatory bodies such as the FDA, EMA, and ICH require the use of validated analytical methods, which provide accurate, precise, and reproducible results essential for regulatory submissions and market approval. This article examines the indispensable role of analytical methods in drug substance development, focusing on their contribution to quality control, assurance, and regulatory compliance. It also explores the interplay between analytical method development and evolving regulatory landscapes. Emerging trends, such as Quality by Design (QbD) and green chemistry principles, are highlighted for their potential to enhance efficiency and sustainability in the development process. By bridging quality and compliance, analytical support not only ensures the safety and efficacy of drug substances but also contributes to the advancement of pharmaceutical innovation.